Literature DB >> 8239283

Alzheimer's disease families with amyloid precursor protein mutations.

M N Rossor1, S Newman, R S Frackowiak, P Lantos, A M Kennedy.   

Abstract

Early onset Familial Alzheimer's Disease (FAD) is an autosomal dominant disease with apparent complete penetrance. It is genetically heterogeneous with some families carrying mutations in the amyloid precursor protein (APP) gene which segregate with the disease. In addition, there is allelic heterogeneity with four mutations associated with FAD. Three mutations have been reported at APP 717, just distal to the C-terminus of the beta-amyloid domain, APP 717 val-ile, APP 717 val-phe, and APP 717 val-gly, which are associated with autopsy-proven Alzheimer's disease (AD). APP 670/671 lies at the N terminus of the beta-amyloid domain and is associated with clinically diagnosed FAD in two Swedish families. FAD tends to have prominent myoclonus and this is shared by the cases with APP mutations. In two unrelated UK families with APP 717 val-ile mutations there was early prominent memory impairment with dyscalculia proceeding to generalized cognitive impairment with a lack of insight. There was a late development of a gait disturbance with extrapyramidal features in some members. Positron emission tomography (PET) with fluorodeoxyglucose demonstrated posterior bitemporal biparietal hypometabolism in one case. Magnetic resonance imaging (MRI) showed generalized cerebral atrophy particularly affecting the temporal lobes and hippocampus. At autopsy, a single case showed extensive beta-amyloid deposition with congophilic angiopathy and widespread senile plaques and neurofibrillary tangles. The cytoskeletal pathology associated with abnormally phosphorylated tau was similar to cases of sporadic AD. In addition, there were widespread cortical and subcortical Lewy bodies. A single family with the APP 717 val-gly mutation also showed prominent myoclonus, lack of insight, and seizures, PET, in a single case, showed classical biparietal bitemporal hypometabolism. Autopsy, in a single case, showed diffuse deposits of beta-amyloid throughout the cortex with frequent neuritic plaques and neurofibrillary tangles. No other inclusion bodies were seen. There was severe congophilic angiopathy. The age at onset of APP mutations is around 50 years of age by contrast to other early onset FAD pedigrees.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239283     DOI: 10.1111/j.1749-6632.1993.tb23052.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  16 in total

1.  Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy.

Authors:  S Moriguchi; T Ishizuka; Y Yabuki; N Shioda; Y Sasaki; H Tagashira; H Yawo; J Z Yeh; H Sakagami; T Narahashi; K Fukunaga
Journal:  Mol Psychiatry       Date:  2016-10-25       Impact factor: 15.992

2.  Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes.

Authors:  Sathish Kumar; Sandesh Singh; Désirée Hinze; Michaele Josten; Hans-Georg Sahl; Martin Siepmann; Jochen Walter
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

3.  Insulin-like growth factor I (IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner.

Authors:  T Niikura; Y Hashimoto; T Okamoto; Y Abe; T Yasukawa; M Kawasumi; T Hiraki; Y Kita; K Terashita; K Kouyama; I Nishimoto
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

Review 4.  Correlating familial Alzheimer's disease gene mutations with clinical phenotype.

Authors:  Natalie S Ryan; Martin N Rossor
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

5.  acn-1, a C. elegans homologue of ACE, genetically interacts with the let-7 microRNA and other heterochronic genes.

Authors:  Chanatip Metheetrairut; Yuri Ahuja; Frank J Slack
Journal:  Cell Cycle       Date:  2017-09-21       Impact factor: 4.534

6.  Attenuated hippocampus-dependent learning and memory decline in transgenic TgAPPswe Fischer-344 rats.

Authors:  Nelson Ruiz-Opazo; Kenneth S Kosik; Lyle V Lopez; Pia Bagamasbad; Lorenz Rb Ponce; Victoria Lm Herrera
Journal:  Mol Med       Date:  2004 Jan-Jun       Impact factor: 6.354

7.  A perfect storm: Converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation.

Authors:  Jeffrey Noebels
Journal:  Epilepsia       Date:  2011-01       Impact factor: 5.864

Review 8.  Therapeutic targeting of the endoplasmic reticulum in Alzheimer's disease.

Authors:  Wayne Chadwick; Nicholas Mitchell; Bronwen Martin; Stuart Maudsley
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

9.  Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease.

Authors:  Mitsuru Shinohara; Shinsuke Fujioka; Melissa E Murray; Aleksandra Wojtas; Matthew Baker; Anne Rovelet-Lecrux; Rosa Rademakers; Pritam Das; Joseph E Parisi; Neill R Graff-Radford; Ronald C Petersen; Dennis W Dickson; Guojun Bu
Journal:  Brain       Date:  2014-03-12       Impact factor: 13.501

Review 10.  Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.

Authors:  Panagiotis Zis; Andre Strydom
Journal:  Free Radic Biol Med       Date:  2017-09-01       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.